|
|
| Biotechnologies Et Génétique > Etude de marché sectorielle |
| Lead Validation Platforms IRCD |
|
|
|
|
€ 1 200,00 |
Editeur
: |
ZZZ - Biovista |
Langue
: |
Anglais |
Date de publication : |
Juillet 2001 |
Taille du document : |
N/A |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pharmacogenomics
160 pages | Décembre 2000 |
The Human Genome Project and numerous corporate and academic human gene sequencing efforts have revealed, among others, that genes exist in the population in numerous mutated forms, some of which |
1 400,00 €
|
| |
| |
The Genomics Outlook To 2005: Transforming pharmaceutical and diagnostic markets
150 pages | Janvier 2002 |
Genomics is quietly transforming the pharmaceutical industry.
Companies are moving from medicinal chemistry based drug discovery and development, to using information provided by genomics.
V |
953,48 €
|
| |
| |
05-001: Improving Sales Rep Performance: A Global Analysis
219 pages | Janvier 2005 |
This report is designed to offer insights on how sales executives can align their sales force organization, recruitment and training in a way that reflects the needs and expectations of scientific cus |
1 520,00 €
|
| |
| |
Bioinformatics
150 pages | Décembre 2000 |
Automation has assaulted several levels of biological research generating vast amounts of data.
Great leaps in DNA sequencing technology and automation led to a dramatic increase in sequence th |
1 400,00 €
|
| |
| |
03-054: Immunohistochemistry Market Benchmarking Survey
90 pages | Octobre 2003 |
This report provides an overview of the most commonly used methods and products for tissue/sample preparation and antigen detection to help suppliers understand researchers’ experiences, preferences a |
680,00 €
|
| |
| |
Combinatorics
150 pages | Décembre 2000 |
Identified by The Economist (*) as the industry to watch for 1997 in the chemicals sector, Combinatorics (also known as combinatorial chemistry) is an emerging platform technology that uses test t |
1 400,00 €
|
| |
| |
DNA Sequencing and PCR Markets
252 pages | Novembre 2004 |
The focus of this report is to describe the specific segment of the life sciences market called DNA sequencing.
This analysis includes all of the generally accepted DNA-oriented analytical activiti |
2 800,00 €
|
| |
| |
03-019: The Market for Microbial Genotyping Products: Research and Testing Applications
183 pages | Juin 2003 |
The report identifies the kits, reagents and instrumentation that are most commonly used for microbial identification and analysis in both the research and testing arenas |
800,00 €
|
| |
| |
Biogenerics: Challenges and Promise
154 pages | Janvier 2005 |
Biogenerics: Challenges and Promise takes an insightful look at the burgeoning biogenerics industry and helps to clarify the complicated regulations that currently govern biogeneric development in bot |
799,20 €
|
| |
| |
Carbohydrate Therapeutics IRCD
pages | Juillet 2001 |
Carbohydrates are the only class of biological molecule (there are four main classes: nucleic acids, proteins, lipids, and carbohydrates - commonly known as sugars), that can be found in direct associ |
1 200,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Lead Validation Platforms IRCD |
|
|
The advent of brute force approaches to lead generation has highlighted a key
bottleneck in drug development. The issue is not how many new compounds can
one make per day, but rather how many can one validate or legitimize as potential
therapeutic candidates for further development. This is the lead validation
problem of drug discovery, and whoever has technologies that can readily screen
many compounds and provide even a 70% accurate continue/discontinue prediction
will be very successful. At present, high throughput screening, which attempts
to address this issue, is based mostly on one-to-one binding assays, where a
target of interest, say HIV protease, is exposed to potential inhibitors in
a high throughput enzyme function test. Although a priori this approach makes sense and forms the cornerstone of current
validation programs, its accuracy is fundamentally constrained by the assumption
that a good in vitro inhibitor of HIV protease in the previous example will
also arrest HIV growth in a patient setting. The next generation of high throughput
lead validation platforms may be based on combinations of automated cellular
assays, and cell-free "molecular drug response cascades".
|
|
I) KNOWLEDGE BLOCK 1: TECHNOLOGY SUMMARY
A) Background
B) The Target and Lead Validation Problem
C) Evolution of the Field
D) The Yeast Two-Hybrid System
E) The Impact of Genomics
F) State of the Art
G) Development Issues
H) Future Developments
I) Technology Examples
II) KNOWLEDGE BLOCK 2: BUSINESS DEVELOPMENT
A) Platform Biotechnologies Current Conditions Market Size Estimates Synopsis of Notable Events in 1998-1999 (YTD)
B) Descriptions of Corporate Activities in 1998-1999 (YTD) Discussion of Corporate Activities in 1998-1999 (YTD)
C) Mergers, Acquisitions and Spin-Out's.
D) Biochip Technology Access Programs
E) Target Identification and Validation Collaborations.
F) Validation of Non-Human Targets.
G) Target Validation and Disease Relevance.
III) KNOWLEDGE BLOCK 3: COMPANY DATABASE
|
|
|
PPLSEN
|
|
|
|
|
